ePrints

SGLT₂ inhibitors - a potential treatment for Alport syndrome

Lookup NU author(s): Dr Holly Mabillard, Professor John SayerORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.Alport syndrome is a rare genetic disease that results in disordered basement membrane type IV collagen resulting in occular and auditory defects as well of progressive kidney disease. Although no 'cure' currently exists, therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression to end-stage kidney disease (ESKD). Clinical trials for treatments in preventing chronic kidney disease have largely been negative over the last two decades until recent trials have shown positive cardiovascular and renal outcomes of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes mellitus. Although marketed as medications for Type 2 diabetes, SGLT2 inhibitors have been found to have additional properties that are nephroprotective which makes them a potential candidate for treatment for those with other forms of progressive kidney disease. This review discusses the evidence for the use of SGLT2 inhibitors as a potential treatment in Alport syndrome that may slow the progression of chronic kidney disease and prevent patients reaching ESKD.

Publication metadata

Author(s): Mabillard H, Sayer JA

Publication type: Article

Publication status: Published

Journal: Clinical Science

Year: 2020

Volume: 134

Issue: 4

Pages: 379-388

Online publication date: 17/02/2020

Acceptance date: 05/02/2020

ISSN (print): 0143-5221

ISSN (electronic): 1470-8736

Publisher: Portland Press

URL: https://doi.org/10.1042/CS20191276

DOI: 10.1042/CS20191276

PubMed id: 32064497

Altmetrics

Share